Prostate-Specific Antigen (Semenogelase)

A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer.
Also Known As:
Semenogelase; Prostate Specific Antigen; Seminin; Kallikrein, hK3; gamma Seminoprotein; Kallikrein hK3; gamma-Seminoprotein; hK3 Kallikrein
Networked: 10408 relevant articles (322 outcomes, 1177 trials/studies)

Relationship Network

Bio-Agent Context: Research Results


1. Lilja, Hans: 106 articles (10/2015 - 08/2002)
2. Partin, Alan W: 92 articles (02/2016 - 02/2002)
3. Scardino, Peter T: 91 articles (08/2015 - 03/2002)
4. D'Amico, Anthony V: 86 articles (06/2015 - 03/2002)
5. Freedland, Stephen J: 80 articles (12/2015 - 02/2002)
6. Catalona, William J: 78 articles (02/2016 - 06/2002)
7. Thompson, Ian M: 78 articles (12/2015 - 06/2003)
8. Schröder, Fritz H: 76 articles (11/2015 - 01/2002)
9. Moul, Judd W: 74 articles (12/2014 - 03/2002)
10. Epstein, Jonathan I: 69 articles (09/2015 - 03/2002)

Related Diseases

1. Prostatic Neoplasms (Prostate Cancer)
2. Neoplasms (Cancer)
3. Carcinoma (Carcinomatosis)
01/01/2008 - "Instead of relying on serum prostate-specific antigen (PSA) to identify patients for prostate biopsy, new laboratory tests are needed that have improved specificity for prostate carcinoma (CaP), allow accurate classification of clinically insignificant CaPs, allow for detection of clinically significant CaP in patients without elevated serum PSA, and allow for identification of aggressive forms of CaP, which may warrant adjunctive or even molecularly targeted therapy in the future. "
12/01/2001 - "The purpose of this study was to evaluate the efficacy of various diagnostic tests including transrectal ultrasound (TRUS), TRUS guided biopsy, digital rectal examination (DRE), prostate specific antigen (PSA), and prostate specific antigen density (PSAD) in detecting prostatic carcinomas. "
05/15/1995 - "This study was undertaken to assess the predictive value of pretreatment prostate-specific antigen (PSA) and the difference between clinical and PSA disease-free status in patients with long-term follow-up after irradiation for prostatic carcinoma. "
12/01/1995 - "The ratio between free and total prostate-specific antigen (PSA) in serum (F/T ratio) was shown to improve the specificity of total serum PSA for the detection of prostate carcinoma in selected populations. "
12/01/1995 - "The ratio between free and total prostate-specific antigen (PSA) in serum (F/T ratio) was shown to improve the differentiation between prostate carcinoma and benign conditions in selected series of patients. "
4. Neoplasm Metastasis (Metastasis)
5. Prostatic Hyperplasia (Benign Prostatic Hyperplasia)

Related Drugs and Biologics

1. Hormones
2. Biological Markers (Surrogate Marker)
3. docetaxel (Taxotere)
4. Alkaline Phosphatase
5. Testosterone (Sustanon)
6. Acid Phosphatase
7. Antigens
8. prostatic acid phosphatase
9. Finasteride (Propecia)
10. abiraterone

Related Therapies and Procedures

1. Prostatectomy (Retropubic Prostatectomy)
2. Radiotherapy
3. Drug Therapy (Chemotherapy)
4. Castration
5. Aftercare (After-Treatment)